Back to News
Market Impact: 0.08
Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. and Encourages Investors to Contact the Firm
Source: globenewswire.com
Legal & LitigationHealthcare & Biotech
Bragar Eagel & Squire said litigation partner Brandon Walker is encouraging investors who incurred losses in Capricor Therapeutics (CAPR) to contact the firm to discuss potential legal options. The notice provides no details on the alleged issues, losses, claims, or potential financial exposure for Capricor.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.15
Ticker Sentiment
CAPR-0.70
More News
- Looters hit 3,000 French businesses. Within hours, the haul was trending on Vinted under the riot’s date
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- J&J prostate cancer drug shows promising tumor responses in early trial
- Exclusive-Boeing supplier dispute has halted 777 freighter production for two months, sources say
- Meta shares are down 9% this week. Here's why Mike Khouw is buying now
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- 2026 Global Markets Outlook: Asset Allocation After the Great Disconnect
- Fintool Alternatives After the Microsoft Acquisition